Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarucizumab Compassionate Use in Japan
NCT02831660Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 3 trial of idarucizumab in hemorrhage, sponsored by Boehringer Ingelheim. Started Jul 2016; status: completed.
02
Drugs
idarucizumab
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT02831660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831660.